Mirtazepine: Heir apparent to amitriptyline?

American Journal of Hospice and Palliative Medicine

Volumn 18, Issue 1, 2001, Pages 42-46

  Davis, Mellar P ^a   Dickerson, E Duke ^b   Pappagallo, Marco ^c   Benedetti, Costantino ^d   Grauer, Phyllis A ^e   Lycan, Jeff ^f  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b Health Sciences and Systems   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e Medicine and Society   (United States)

^f USA   (United States)

Author keywords

anti depressants; Mirtazepine; noradrenergic and specific serotonergic receptor antagonism (NaSSa); palliative care; pharmacotherapy; portmanteau; selective serotonin reuptake inhibitor (SSRI)

Indexed keywords

AMITRIPTYLINE; DRUG DERIVATIVE; ESSENTIAL DRUG; HISTAMINE H1 RECEPTOR ANTAGONIST; MIANSERIN; MIRTAZAPINE; TRICYCLIC ANTIDEPRESSANT AGENT;

CLASSIFICATION; DRUG COST; ECONOMICS; HUMAN; METHODOLOGY; PATIENT SELECTION; REVIEW; TERMINAL CARE;

AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DRUG COSTS; DRUGS, ESSENTIAL; HISTAMINE H1 ANTAGONISTS; HUMANS; MIANSERIN; PATIENT SELECTION; TERMINAL CARE;

EID: 0035223202     PISSN: 10499091     EISSN: None     Source Type: Journal    
DOI: 10.1177/104990910101800111     Document Type: Article

References (10)

1. Abed RT, Cooper M: Mirtazepine causing hyperphagia. British J Psychiatry. 1999; 174(2): 181-182.
2. Bailer U, Praschak-Reider N, Pezawas L, Kasper S: Mirtazepine in inpatient treatment of depressed patients. Wien Klin Wochenschr. 1998; 110(18): 646-650.
3. Brannon GE, Stone KD: The use of mirtazapine in a patient with chronic pain. J Pain & Symptom Manage. 1999; 18(5): 382-385.
4. Burrows GD, Kremer CM: Mirtazapine: Clinical advantages in the treatment of depression. J Clin Psychopharmacol. 1997; 1: 34-39.
5. Curran S, de Pauw K: Selecting an antidepressant for use in a patient with epilepsy: Safety considerations. Drug Safety. 1998; 18(2): 125-133.
6. de Boer TH: The pharmacologic profile of mirtazapine. J Clin Psychiatry. 1996; 57: 19-25.
7. Gelenberg AJ, Laukes C, McGahuy C, et al.: Mirtazapine substitution in SSRI-induced sexual dysfunction. J Clin Psychiatry. 2000; 61(5): 356-360.
8. Kent JM: SNaRIs, NaSSAS, and NaRIs: New agents for the treatment of depression. Lancet. 2000; 355: 911-918.
9. O”Reardon JP, Brunswick DJ, Amsterdam JD: Treatment-resistant depression in the age of serotonin: Evolving strategies. Current Opinion in Psychiatry. 2000; 13(1): 93-98.
10. Puzantian T: Mirtazapine, an antidepressant. American J Health-System Pharmacy. 1998; 55(1): 44-49.